Effect of trandolapril on regression of retinopathy in hypertensive patients with type 2 diabetes: a prespecified analysis of the benedict trial.

Journal of Ophthalmology
Piero RuggenentiGiuseppe Remuzzi

Abstract

Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4-60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18-6.42), P = .0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy.

References

Feb 1, 1996·Archives of Ophthalmology·S M Brown, L M Jampol
Feb 12, 1998·Microcirculation : the Official Journal of the Microcirculatory Society, Inc·R SatcherJ H Hartwig
Apr 16, 1998·Diabetes Care·L P AielloR Klein
Sep 13, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·R C TempleA Glenn
Jan 17, 2002·Diabetologia·M PortaUNKNOWN EURODIAB Prospective Complications Study Group
Apr 11, 2003·Diabetologia·B V BuiA J Vingrys
Sep 10, 2004·The Journal of Clinical Endocrinology and Metabolism·Aneliya ParvanovaPiero Ruggenenti
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Jan 30, 2007·Diabetes Care·Auni JuutilainenMarkku Laakso

❮ Previous
Next ❯

Citations

Jun 8, 2012·Current Hypertension Reports·Vasiliki KatsiIoannis Kallikazaros
Jan 2, 2013·Acta Diabetologica·Francesco BandelloClaudia Del Turco
Feb 11, 2015·The Lancet. Diabetes & Endocrinology·Bin WangYan-Gang Wang
Aug 7, 2014·Ophthalmology·Kenshiro AraoShin-ichi Momomura
Feb 1, 2015·The Cochrane Database of Systematic Reviews·Diana V DoRobert N Frank
Aug 22, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Jian RongJing Chen
Aug 3, 2019·The International Journal of Health Planning and Management·Fei QinRong Shi

❮ Previous
Next ❯

Methods Mentioned

BETA
urine collections
ion exchange

Software Mentioned

BENEDICT
SAS

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.